Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Purpose of review: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the formation of kidney cysts and kidney enlargement, which progresses to kidney failure by the fifth to seventh decade of life in a majority of patients. Disease progression is evaluate...

Full description

Bibliographic Details
Main Authors: Navdeep Tangri, Ingrid Hougen, Ahsan Alam, Ronald Perrone, Phil McFarlane, York Pei
Format: Article
Language:English
Published: SAGE Publishing 2017-03-01
Series:Canadian Journal of Kidney Health and Disease
Online Access:https://doi.org/10.1177/2054358117693355
id doaj-458b410a103548018de9618d1712fd07
record_format Article
spelling doaj-458b410a103548018de9618d1712fd072020-11-25T03:33:15ZengSAGE PublishingCanadian Journal of Kidney Health and Disease2054-35812017-03-01410.1177/205435811769335510.1177_2054358117693355Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseNavdeep Tangri0Ingrid Hougen1Ahsan Alam2Ronald Perrone3Phil McFarlane4York Pei5Department of Community Health Sciences, University of Manitoba, Winnipeg, CanadaRenal Program, Seven Oaks General Hospital, Winnipeg, Manitoba, CanadaRoyal Victoria Hospital, Montreal, Quebec, CanadaTufts Medical Center, Boston, MA, USASt. Michael’s Hospital, University of Toronto, Toronto, CanadaUniversity Health Network, University of Toronto, Ontario, CanadaPurpose of review: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the formation of kidney cysts and kidney enlargement, which progresses to kidney failure by the fifth to seventh decade of life in a majority of patients. Disease progression is evaluated primarily through serum creatinine and estimated glomerular filtration rate (eGFR) measurements; however, it is known that serum creatinine and eGFR values typically do not change until the fourth or fifth decade of life. Until recently, therapy only existed to target complications of ADPKD. As therapeutic agents continue to be investigated for use in ADPKD, a suitable biomarker of disease progression in place of serum creatinine is needed. Sources of information: This review summarizes recent research regarding the use of total kidney volume as a biomarker in ADPKD, as presented at the Canadian Society of Nephrology symposium held in April 2015. Findings: Measurement of patients’ total kidney volume made using ultrasound (US) or magnetic resonance imaging (MRI) has been shown by the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) study to be directly correlated with both increases in cyst volume and change in glomerular filtration rate (GFR). Additional studies have shown total kidney volume to have an association with complications of ADPKD as well. Limitations: Areas for further study continue to exist in comparison of methods of measuring total kidney volume. Implications: We believe that the evidence suggests that total kidney volume may be an appropriate surrogate marker for ADPKD disease progression.https://doi.org/10.1177/2054358117693355
collection DOAJ
language English
format Article
sources DOAJ
author Navdeep Tangri
Ingrid Hougen
Ahsan Alam
Ronald Perrone
Phil McFarlane
York Pei
spellingShingle Navdeep Tangri
Ingrid Hougen
Ahsan Alam
Ronald Perrone
Phil McFarlane
York Pei
Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Canadian Journal of Kidney Health and Disease
author_facet Navdeep Tangri
Ingrid Hougen
Ahsan Alam
Ronald Perrone
Phil McFarlane
York Pei
author_sort Navdeep Tangri
title Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
title_short Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
title_full Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
title_fullStr Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
title_full_unstemmed Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
title_sort total kidney volume as a biomarker of disease progression in autosomal dominant polycystic kidney disease
publisher SAGE Publishing
series Canadian Journal of Kidney Health and Disease
issn 2054-3581
publishDate 2017-03-01
description Purpose of review: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the formation of kidney cysts and kidney enlargement, which progresses to kidney failure by the fifth to seventh decade of life in a majority of patients. Disease progression is evaluated primarily through serum creatinine and estimated glomerular filtration rate (eGFR) measurements; however, it is known that serum creatinine and eGFR values typically do not change until the fourth or fifth decade of life. Until recently, therapy only existed to target complications of ADPKD. As therapeutic agents continue to be investigated for use in ADPKD, a suitable biomarker of disease progression in place of serum creatinine is needed. Sources of information: This review summarizes recent research regarding the use of total kidney volume as a biomarker in ADPKD, as presented at the Canadian Society of Nephrology symposium held in April 2015. Findings: Measurement of patients’ total kidney volume made using ultrasound (US) or magnetic resonance imaging (MRI) has been shown by the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) study to be directly correlated with both increases in cyst volume and change in glomerular filtration rate (GFR). Additional studies have shown total kidney volume to have an association with complications of ADPKD as well. Limitations: Areas for further study continue to exist in comparison of methods of measuring total kidney volume. Implications: We believe that the evidence suggests that total kidney volume may be an appropriate surrogate marker for ADPKD disease progression.
url https://doi.org/10.1177/2054358117693355
work_keys_str_mv AT navdeeptangri totalkidneyvolumeasabiomarkerofdiseaseprogressioninautosomaldominantpolycystickidneydisease
AT ingridhougen totalkidneyvolumeasabiomarkerofdiseaseprogressioninautosomaldominantpolycystickidneydisease
AT ahsanalam totalkidneyvolumeasabiomarkerofdiseaseprogressioninautosomaldominantpolycystickidneydisease
AT ronaldperrone totalkidneyvolumeasabiomarkerofdiseaseprogressioninautosomaldominantpolycystickidneydisease
AT philmcfarlane totalkidneyvolumeasabiomarkerofdiseaseprogressioninautosomaldominantpolycystickidneydisease
AT yorkpei totalkidneyvolumeasabiomarkerofdiseaseprogressioninautosomaldominantpolycystickidneydisease
_version_ 1724563693947060224